PT1879612E - Utilização de péptidos nativos e de seus derivados optimizados em vacinação - Google Patents

Utilização de péptidos nativos e de seus derivados optimizados em vacinação Download PDF

Info

Publication number
PT1879612E
PT1879612E PT06743108T PT06743108T PT1879612E PT 1879612 E PT1879612 E PT 1879612E PT 06743108 T PT06743108 T PT 06743108T PT 06743108 T PT06743108 T PT 06743108T PT 1879612 E PT1879612 E PT 1879612E
Authority
PT
Portugal
Prior art keywords
vaccination
optimized
native
peptides
native peptides
Prior art date
Application number
PT06743108T
Other languages
English (en)
Inventor
Kostantinos Kosmatopoul Kostas
Original Assignee
Vaxon Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxon Biotech filed Critical Vaxon Biotech
Publication of PT1879612E publication Critical patent/PT1879612E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001122—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464457—Telomerase or [telomerase reverse transcriptase [TERT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
PT06743108T 2005-05-09 2006-05-09 Utilização de péptidos nativos e de seus derivados optimizados em vacinação PT1879612E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05290984 2005-05-09

Publications (1)

Publication Number Publication Date
PT1879612E true PT1879612E (pt) 2009-06-30

Family

ID=37396914

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06743108T PT1879612E (pt) 2005-05-09 2006-05-09 Utilização de péptidos nativos e de seus derivados optimizados em vacinação

Country Status (13)

Country Link
US (2) US8663645B2 (pt)
EP (1) EP1879612B1 (pt)
JP (1) JP5435938B2 (pt)
CN (1) CN101171032B (pt)
AT (1) ATE427117T1 (pt)
BR (1) BRPI0608768B1 (pt)
CA (1) CA2606871C (pt)
DE (1) DE602006006046D1 (pt)
DK (1) DK1879612T3 (pt)
ES (1) ES2323895T3 (pt)
PL (1) PL1879612T3 (pt)
PT (1) PT1879612E (pt)
WO (1) WO2006120038A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008010010A1 (en) 2006-07-12 2008-01-24 Vaxon Biotech Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy
CN102153658A (zh) * 2011-01-19 2011-08-17 上海科医联创生物科技有限公司 肿瘤抗原、dc肿瘤疫苗及其制备方法
WO2013036201A1 (en) * 2011-09-06 2013-03-14 Agency For Science, Technology And Research Polypeptide vaccine
IL293135A (en) 2015-05-13 2022-07-01 Agenus Inc A preparation containing at least two different complexes of purified stress protein linked to an antigenic peptide
EP3400954A1 (en) * 2017-05-09 2018-11-14 Vaxon Biotech Vaccine targeting a cryptic tert epitope, for treating lung cancer in a hla-a*0201-positive never-smoker or light-former smoker patient
EP3400959A1 (en) * 2017-05-09 2018-11-14 Vaxon Biotech Use of a vaccine targeting a cryptic tert epitope, for treating cancer in a hla-a*0201-positive patient having a non-immunogenic tumor expressing tert
US20200147195A1 (en) * 2017-05-26 2020-05-14 The Wistar Institute Of Anatomy And Biology Dtert vaccines and methods of treatment using the same
AU2019261451A1 (en) 2018-04-26 2020-12-03 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
US11161892B1 (en) 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001241533A1 (en) * 2000-02-15 2001-08-27 The Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
CA2453880A1 (en) * 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
FR2837837B1 (fr) * 2002-03-28 2006-09-29 Roussy Inst Gustave Epitopes peptidiques communs a des antigenes d'une meme famille multigenique
FR2838742B1 (fr) * 2002-04-23 2004-07-09 Inst Nat Sante Rech Med Epitopes t de l'antigene epha2

Also Published As

Publication number Publication date
CA2606871C (en) 2014-06-03
WO2006120038A3 (en) 2007-07-19
BRPI0608768B1 (pt) 2019-08-20
ATE427117T1 (de) 2009-04-15
BRPI0608768A2 (pt) 2010-01-26
EP1879612B1 (en) 2009-04-01
ES2323895T3 (es) 2009-07-27
WO2006120038A2 (en) 2006-11-16
US20140178421A1 (en) 2014-06-26
DK1879612T3 (da) 2009-07-20
US8663645B2 (en) 2014-03-04
CN101171032B (zh) 2012-02-29
CN101171032A (zh) 2008-04-30
US20080254051A1 (en) 2008-10-16
JP2008540483A (ja) 2008-11-20
CA2606871A1 (en) 2006-11-16
EP1879612A2 (en) 2008-01-23
DE602006006046D1 (de) 2009-05-14
JP5435938B2 (ja) 2014-03-05
PL1879612T3 (pl) 2009-08-31

Similar Documents

Publication Publication Date Title
PT1879612E (pt) Utilização de péptidos nativos e de seus derivados optimizados em vacinação
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
UA103751C2 (ru) Иммуногенный пептид для иммунотерапии
MX2009009342A (es) Metodo novedoso y composiciones.
WO2009041832A3 (en) Vaccines and vaccine components for inhibition of microbial cells
WO2009072610A1 (ja) 癌ワクチン組成物
WO2009026465A3 (en) Composition and methods of making and using influenza proteins
PT1791571E (pt) Péptidos radiofluorados
MX364777B (es) Péptidos cancerígenos universales derivados de telomerasa.
MX2015016564A (es) Derivados de peptido similar al glucaton tipo 1 (glp-1) y uso de los mismos.
ECSP066912A (es) Formulaciones de dispersiones sólidas de acetato de bazedoxifeno
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
WO2010085700A3 (en) Treatment for obesity
IL189452A0 (en) Therapy with cd4 binding peptides and radiation
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
NZ594198A (en) Neil3 peptides and vaccines including the same
MX2009007572A (es) Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y.
NO20072705L (no) Alfa-tymosinpeptider som cancervaksineadjuvanser
NZ596501A (en) Casb7439 constructs
NZ732301A (en) Peptide compound, preparation method therefor, and application thereof
MX355759B (es) Peptidos topk y vacunas que incluyen los mismos.
GB2429711A (en) Heart and skeletal muscle inflammation (HSMI) virus
WO2010056144A3 (en) Foxp3+ natural kiler t-cells and the treatment of immune related diseases
WO2009072555A1 (ja) 癌ワクチン
UA102274C2 (ru) Эпитопный пептид rab6kifl/kif20a и вакцины, которые его содержат